Cargando…
Effect of donepezil for dementia prevention in Parkinson's disease with severe hyposmia (The DASH-PD study): A randomized long-term placebo-controlled trial
BACKGROUND: Dementia greatly contributes to poor prognosis in patients with Parkinson's disease (PD). We previously reported that severe olfactory dysfunction may be a good predictor of Parkinson's disease dementia (PDD). In this trial, we investigated whether early administration of donep...
Autores principales: | Baba, Toru, Takeda, Atsushi, Murakami, Aya, Koga, Tadashi, Isomura, Tatsuya, Mori, Etsuro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289637/ https://www.ncbi.nlm.nih.gov/pubmed/35860451 http://dx.doi.org/10.1016/j.eclinm.2022.101571 |
Ejemplares similares
-
Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial
por: Mori, Etsuro, et al.
Publicado: (2012) -
Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial
por: Ikeda, Manabu, et al.
Publicado: (2015) -
Hyposmia Is Associated with RBD for PD Patients with Variants of SNCA
por: Li, Yuanyuan, et al.
Publicado: (2017) -
Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia
por: Beach, Thomas G., et al.
Publicado: (2020) -
Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial
por: Mori, Etsuro, et al.
Publicado: (2015)